

# Welcome to the Summit



Kenneth H. Mayer  
November 26<sup>th</sup>, 2012




**Forum for  
Collaborative HIV Research**




# What a difference 2 years make

- iPrEX, other PrEP studies
- HPTN 052
- The “Cascade”
- ACA
- ECHPP
- Home HIV self-testing
- FDA approval of PrEP
- Presidential re-election
- USPHS & routine testing




# Clinical Trial Evidence that Antiretroviral Drugs Prevent HIV Transmission



\*Other trials were negative

# HPTN 052: HIV Transmission by HAART but many were not monogamous



# PrEP (Like ART) Works When Taken

	Blood Samples With Tenofovir Detected, %	HIV Protection Efficacy in Randomized Comparison,%
Partners PrEP*[1]	81	75
TDF2[2]	79	62
iPrEx[3]	51	44
FEM-PrEP[4]	26	6


\*TDF/FTC arm

**There is a clear dose-response  
between evidence of PrEP use and efficacy**

1. Baeten JM, et al. N Engl J Med. 2012;[Epub ahead of print]. 2. Thigpen MC, et al N Engl J Med. 2012;[Epub ahead of print]. 3. Grant RM, et al. N Engl J Med. 2010;363:2587-2599. 4. Van Damme L, et al N Engl J Med. 2012;[Epub ahead of print].

# CDC: HIV-Infected Persons Engaged in Selected Stages of the Continuum of Care (2009)




CDC and Prevention National HIV Surveillance System



n=1,148,200 HIV-infected persons, 18% of whom are unaware of their infection.

Hall HI, et al. 19<sup>th</sup> IAC. Washington, DC, 2012. Abstract FrLBX05.

# El-Sadr W et al. N Engl J Med 2010;10.1056






## HIV incidence in Black MSM (HPTN 061)

---

- HIV incidence was high: 2.8%; 95% CI: 1.8, 4.1
  - **Young men, 18-30: 5.9% (95% CI: 3.6, 9.1)**
  - **Those reporting URA: 4.9% (95% CI: 3.0, 7.4)**
  - **Gay/homosexual and those with male partners only: 4.3% (95% CI: 2.6, 6.7)**
  - **Those with STIs: 6.0% (95% CI: 2.4, 12.5)**
- Targeted, tailored and culturally appropriate combination HIV prevention strategies (behavioral, social, structural and biomedical) are urgently needed.



# Trends in HIV Infection and Death among People Reported with HIV/AIDS by Year: Massachusetts, 2000–2011



Note: 2011 Death data are preliminary

Data Source: MDPH HIV/AIDS Surveillance Program; Data as of 9/1/12

# What we need to know

- How to best expand testing, linkage and retention in care
- How to roll out self-testing to ensure increased serostatus knowledge
- The role of PrEP as part of a prevention package
- Which behavioral interventions improve medication adherence, decrease risk taking
- How ACA implementation will affect AIDS care, including Ryan-White reauthorization